Teva Pharmaceutical Industries Ltd (NASDAQ:TEVA)‘s stock had its “buy” rating reaffirmed by research analysts at Jefferies Group in a report released on Friday. They currently have a $61.00 price objective on the stock. Jefferies Group’s target price suggests a potential upside of 22.12% from the stock’s previous close. Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) stock opened today at $49.95 and is currently trading at $49.48. The stock showed a positive weekly performance of 0.62%.
On May 15, 2014, the stockholders of Repligen Corporation (NASDAQ:RGEN) approved an amendment to the Company’s Certificate of Incorporation (the “Certificate”) to increase the aggregate number of shares of common stock which the Company will have authority to issue from 40,000,000 to 80,000,000 shares. To give effect to this amendment, on May 16, 2014, the Company filed a certificate of amendment (the “Certificate of Amendment”) to the Certificate with the Secretary of State of the State of Delaware. A copy of the Certificate of Amendment is filed as Exhibit 3.1 to this Current Report on Form 8-K and incorporated by reference herein. Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) stock opened at $298.02, in current trading session and currently is at $297.00, by losing -1.70%. The 52 week range of $206.30 – $352.49. Company’s market capitalization is 29.68 billion.
Sanofi SA (ADR) (NYSE:SNY) Pasteur, the vaccines division of Sanofi (EURONEXT: SAN and NYSE: SNY), presented Phase II trial (H-030-012) results for an investigational vaccine for the prevention of Clostridium difficile (C. diff) infection (CDI) at the 114th General Meeting of the American Society for Microbiology (ASM). Sanofi SA (ADR) (NYSE:SNY) stock is currently trading at $52.69. The EPS of the stock is 1.59. Company’s market capitalization is 140.38 billion.
Merck & Co., Inc. (NYSE:MRK) known as MSD outside the United States and Canada, and Endocyte Inc. announced the withdrawal of conditional marketing authorization applications (CMA) from the European Medicines Agency (EMA) for vintafolide and companion imaging components, imaging agent etarfolatide and intravenous (IV) folic acid, for the treatment of adult patients with folate receptor-positive, platinum-resistant ovarian cancer, in combination with pegylated liposomal doxorubicin (PLD). Merck & Co., Inc. (NYSE:MRK) stock opened the session at $56.22, and now is at $56.07. The 52 week range of the Merck & Co., Inc. (NYSE:MRK) stock remained $44.62 – $59.84 and the day range was $55.92 – $56.26.
Bayer AG (NASDAQ:BAYRY) released its earnings data on Tuesday. The company reported $2.35 earnings per share for the quarter, missing the analysts’ consensus estimate of $2.47 by $0.12, Analyst Ratings Network reports. Bayer AG (ADR) (OTCMKTS:BAYRY) stock opened today at $141.08 and is currently trading at $140.97.
Leave a Reply